Refine by
Alzheimer S Articles & Analysis
185 news found
Versatile compound shows promise in drug synthesis, metal chelation, antioxidant activity, and moreChangsha, China – May 22, 2025– Hunan Huateng Pharmaceutical Co., Ltd., a leading global supplier of PEG derivatives and pharmaceutical intermediates, is proud to offer high-purity N-Benzylhydroxylamine Hydrochloride (CAS 29601-98-7) to researchers and pharmaceutical developers worldwide. This ...
Investorideas.com (www.investorideas.com) Biotech Stock News Bites - Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines is one of NASDAQ's top gainers today and the stock is trending on Yahoo Finance, currently trading at $3.8955, up $1.6955 or 77.0682%. The stock had a morning high of $5.47 on volume of over 36 Million/. The Company's CEO, ...
In today’s fast-paced and stressful society, the prevalence of anxiety and depression has become a significant concern. ...
The 87th China International Medical Equipment Fair (CMEF) opened on 14 May at the National Convention and Exhibition Centre (Shanghai). The exhibition is a trendsetter in the global medical device industry and a "top tier" medical event, with brand representatives from more than 20 countries and regions from around the world showcasing sophisticated products spanning the entire industry chain ...
In the wake of the COVID-19 pandemic, BOC Sciences, the world's reputed chemical supplier, declares that it will increase production to offer pharmaceutical impurity standards in bulk to satisfy unmet demands. Innovations in manufacturing processes, more complicated formulations, and increasingly complex global supply chains are just some of the factors making it more difficult for companies to ...
The companies will jointly develop the compounds for the multiple system atrophy (MSA) and Parkinson’s disease (PD) indications based on early-stage clinical studies, and consider exploring additional indications based on clinical outcomes. ...
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. patent 11,472,776 (the ‘776 patent) titled, “Novel Quinazolinones that Inhibit the Formation of Tau ...
Led by a team of experienced entrepreneurs with successful track records in biotech, pharmaceuticals, and device technology, the company’s mission is to pave the way in treating complex CNS disorders, including Alzheimer’s disease, cognitive aging, Lewy body dementia, Parkinson’s disease, and ALS. ...
They will also discuss the Company’s ongoing commercial launch strategy for IGALMI™ (dexmedetomidine) sublingual film. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and ...
“We anticipate top-line data from SERENITY III as well as our TRANQUILITY II trial for Alzheimer’s-related agitation in the first half of 2023. These two near-term pivotal data readouts further reinforce the potential of BXCL501 to address the unmet medical needs of millions of ...
Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases CY6463 favorable tolerability and safety profile was confirmed Ariana Pharma, a leading Artificial Intelligence (AI) drug development company, in collaboration with Cyclerion Therapeutics, presented today safety and pharmacodynamic results ...
“I’ve seen the consequences PPD can have on a mother’s ability to care for herself, her baby, and her family in a way that can have a generational impact. ...
Webcast Information A live webcast of the presentation can be accessed on the investor page of Sage's website at investor.sagerx.com, where it will be available for up to 30 days, and the investor page of Biogen’s website at investors.biogen.com. About Sage Therapeutics Sage Therapeutics is a biopharmaceutical company fearlessly leading the way to create a world with ...
Targeting neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s Identified two lead cannabinoid analog compounds for in vivo studies NSERC grant funding supports InMed’s collaborative research projects with Dr. ...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its licensing partner Roche (SIX: RO, ROG; OTCQX: RHHBY) provided an update on the GRADUATE I and II studies evaluating gantenerumab in people with early Alzheimer’s disease (AD). The studies did not meet their primary endpoint of slowing clinical decline. ...
His vast experience and proven track record will greatly support Elucid’s continued work in combating cardiovascular disease,” said Blake Richards, chief executive officer, Elucid. ...
ByElucid
Altoida, Inc., the precision neurology company pioneering non-invasive brain health measurement and neurological disease diagnostics with AI and augmented reality (AR), today announced that management will be presenting at the upcoming conferences: BioFuture Panel Title: New Diagnostics: Revolutionizing Care in Alzheimer’s Date/Time: Wednesday, Nov. 9, ...